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Cdc42 is a Ras-related GTPase that plays an important role in the regulation of a range of cellular functions, including cell mi-
gration, proliferation, and survival. Consistent with its critical functions in vitro, the inactivation of Cdc42 in mice has been
shown to result in embryonic lethality at embryonic day 6.5 (E6.5) before blood vessel formation. To determine the role of Cdc42
in new blood vessel formation, we have generated vascular endothelial cell (EC)-specific Cdc42 knockout mice by crossing
Cdc42flox/flox mice with Tie2-Cre mice. The deletion of Cdc42 in ECs caused embryonic lethality with vasculogenesis and angio-
genesis defects. We observed that Cdc42 is critical for ECmigration and survival but not for cell cycle progression. Moreover, we
found that the inactivation of Cdc42 in ECs decreased the level of vascular endothelial growth factor receptor 2 (VEGFR2) pro-
tein on the EC surface and promoted the production of a 75-kDamembrane-associated C-terminal VEGFR2 fragment. Using
cultured primary mouse ECs and human umbilical vein ECs, we have demonstrated that the deletion of Cdc42 increased AD-
AM17-mediated VEGFR2 shedding. Notably, inhibition of ADAM17 or overexpression of VEGFR2 can partially reverse Cdc42
deletion-induced EC apoptosis. These data indicate that Cdc42 is essential for VEGFR2-mediated signal transduction in blood
vessel formation.
Aberrant blood vessel formation induces embryonic lethality aswell as contributing to the pathogenesis of many human dis-
eases, including coronary heart disease, diabetes, and cancer (1–
3). Blood vessels can form by vasculogenesis, in which a primitive
vascular network is formed by pluripotent mesenchymal progen-
itor differentiation and proliferation in situ in avascular tissue, or
by angiogenesis, which refers to the growth of new blood vessels
from preexisting vessels (4–6). Vascular endothelial cells (ECs)
line the whole vascular system and play central roles in angiogen-
esis and vasculogenesis. Many EC surface receptors and their li-
gands have been found to play essential roles in the formation of
new blood vessels; these receptors include the vascular endothelial
growth factor receptor (VEGFR), Tie1 (tyrosine kinase with im-
munoglobulin-like and EGF-like domains 1) and Tie2 receptors,
Eph receptors, integrins, and Notch (7–9). However, there is still
much to learn regarding the intracellular signal transduction
mechanisms involved in angiogenesis and vasculogenesis.
VEGF plays a key role in regulating angiogenesis and vasculo-
genesis in both embryogenesis and pathogenesis in human dis-
eases, such as cancer metastasis (2, 6). After binding to its major
receptor, VEGFR2, in ECs, VEGF induces the dimerization of
VEGFR2 and activates many different signal transduction path-
ways. Rho GTPase-mediated signal transduction is one of the
pathways activated by VEGFR2. Cdc42 is a Rho GTPase family
member that cycles between an inactive GDP-bound state and an
active GTP-bound state in response to extracellular stimuli (10,
11). VEGF stimulation induces time-dependent activation of
Cdc42 in human umbilical vein endothelial cells (HUVECs) (4,
12, 13). EC morphogenesis, including vacuole and lumen forma-
tion, is important for angiogenesis. A series of seminal in vitro
studies has demonstrated that Cdc42 and its downstream effec-
tors, including p21-activated kinase 2 (PAK2), PAK4, partition-
ing-defective 3 homolog (Par3), and Par6, are crucial for EC mor-
phogenesis (14, 15). Overexpression of either constitutively active
Cdc42 or dominant negative Cdc42 by use of a recombinant ade-
novirus (Ad) has been shown to inhibit EC vacuole formation in
experiments utilizing a 3-dimensional extracellular matrix, sug-
gesting that proper cycling of Cdc42 between its GDP- and GTP-
bound states is required for EC morphogenesis and angiogenesis
(16). A recent study using cultured mouse embryonic stem cells
also demonstrated the importance of Cdc42 for vasculogenesis
through its downstream effectors protein kinase C and glycogen
synthase kinase-3 (17).
Accumulating evidence indicates that Cdc42 plays an impor-
tant role in EC function and vascular development (13, 18–22);
however, far less is known about the in vivo functions of Cdc42 in
blood vessel formation during embryonic development. Mice
with a total knockout of Cdc42 die before embryonic day 6.5
(E6.5) (23), which limits the usefulness of this mouse model in
studying the role of Cdc42 in the later stages of embryonic devel-
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opment and in adulthood. In this study, we used a conditional
Cdc42 knockout mouse model to examine these critical issues.
The mouse mutant, in which the Cdc42 locus was modified by
adding 2 flanking loxP sites (24), was crossed with Tie2-Cre trans-
genic mice that expressed Cre recombinase in their ECs (25, 26).
Our results revealed that Cdc42 is essential for vasculogenesis dur-
ing embryonic development. Cdc42 deletion reduced the survival
and migration of ECs, leading to defects in blood vessel formation.
The upregulation of disintegrin and metalloprotease 17 (ADAM17)-
mediated VEGFR2 shedding, reducing the density of VEGFR2 on the
cell surface, is an underlying molecular mechanism for the vascular
defects in Cdc42 knockout embryos.
MATERIALS AND METHODS
Generation of Cdc42 EC-specific knockout mice. Cdc42flox/flox mice
were generated by inserting two LoxP sites to flank exon 2 of the Cdc42
gene (24). Cdc42 EC-specific knockout mice were created by crossing
Cdc42flox/flox mice with Tie2-Cre mice (mixed C57BL/6 S129/S4 back-
ground) (24–26). The deletion of exon 2 upon Cre-mediated recombina-
tion results in a truncated small peptide that lacks the majority of the
Cdc42 amino acid residues. All study protocols were approved by the
Institutional Animal Care and Use Committee of the Texas A&M Health
Science Center and conform to the NIH Guide for the Care and Use of
Laboratory Animals (27).
siRNA transfection. HUVECs (2  105/well) were plated in 6-well
plates and were incubated with various small interfering RNAs (siRNAs)
(20 nM) and HiPerFect transfection reagent (Qiagen) for 72 h, according
to the manufacturer’s instructions. Subsequently, HUVECs were used for
tube formation, bromodeoxyuridine (BrdU) incorporation, or biotinyla-
tion assays, and aliquots of cell lysates were blotted to confirm the effi-
ciency of RNA interference (RNAi).
Generation of a VEGFR2-expressing adenovirus. Hemagglutinin
(HA)-tagged wild-type VEGFR2 was released from the pKH3 vector by
XhoI and SalI restriction enzymes and was then subcloned into the
pAdTrack-CMV vector. After homologous recombination, the AdEasy-1
vector (Stratagene), which contains HA-tagged wild-type VEGFR2, was
transfected into Ad-293 cells for virus packaging. Ten days later, adeno-
virus was harvested from cell lysates and was stored in a80°C freezer for
future use (28, 29).
Tube formation assay. HUVECs transfected with siRNA or infected
with adenoviruses were plated on 24-well plates coated with a thin layer of
Matrigel (BD Biosciences) at 5  104 cells/well in EBM-2 medium
(Lonza). HUVECs were then cultured for 18 h in a 37°C humidified CO2
incubator to form tube structures. The tube structures were photo-
graphed under a microscope with a charge-coupled device (CCD) cam-
era, and the lengths of the tubes were determined as described previously
(30).
Isolation and culture of primary ECs ofmice.ECs were isolated from
neonatal Cdc42flox/flox mice by using magnetic beads (Invitrogen) cou-
pled with rat anti-mouse platelet endothelial cell adhesion molecule 1
(anti-PECAM-1) (BD Biosciences), as described previously (31, 32). ECs
were cultured in EBM-2 endothelial cell medium. The purity of the ECs
was confirmed by identifying EC markers (vascular endothelial cadherin
[VE-cadherin]) using flow cytometry.
Flow cytometric analysis. Confluent cultured ECs were detached us-
ing 0.05% EDTA and were washed with phosphate-buffered saline (PBS).
Subsequently, ECs were fixed in 4% paraformaldehyde (PFA) and were
incubated with normal rabbit IgG or an antibody against VE-cadherin
(Enzo). Cells were washed, stained with Alexa Fluor 488-conjugated goat
anti-rabbit IgG (Invitrogen), and analyzed using a BD Biosciences
FACSCalibur flow cytometer. For analysis of apoptosis, HUVECs were
treated with scrambled siRNA, Cdc42 siRNA, or Cdc42 siRNA plus
ADAM17 siRNA. The siRNA-treated HUVECs were stained with annexin
V by using a fluorescein isothiocyanate (FITC)-annexin V staining kit
(Invitrogen) and were then analyzed with a BD Biosciences FACSCalibur
flow cytometer.
X-Gal and PECAM-1 whole-mount staining. Isolated embryos were
fixed in 4% PFA in PBS and were then stained with 1 mg/ml 5-bromo-4-
chloro-3-indolyl--D-galactopyranoside (X-Gal) overnight at room tem-
perature as described previously (28). For PECAM-1 whole-mount stain-
ing, the 4% PFA-fixed embryos and yolk sacs were dehydrated by
methanol, and the endogenous peroxidases were quenched with 5% H2O2
in methanol for 4 to 5 h. After rehydration in methanol and PBS, samples
were blocked in 3% nonfat dry milk with 0.1% Triton X-100 in PBS. The
embryos were then incubated with anti-PECAM-1 (1:100) antibodies (BD
Biosciences) at 4°C overnight, followed by staining with horseradish per-
oxidase (HRP)-conjugated secondary antibodies.
TUNEL assay. Embryo sections or isolated ECs infected with Ad-
LacZ, or with Ad-Cre with or without TAPI-1 treatment, were examined
for apoptosis by a terminal deoxynucleotidyltransferase-mediated dUTP-
biotin nick end-labeling (TUNEL) assay by using the In Situ cell death
detection kit (Roche) according to the product instructions, as described
previously (33).
Real-time PCR. Cultured mouse primary ECs were infected with Ad-
LacZ or Ad-Cre. Three days later, total RNA was isolated by using an
RNeasy kit (Qiagen) according to the manufacturer’s instructions. The
samples were then reverse transcribed to cDNA, which was assayed by
real-time PCR experiments using SYBR green master mix (Applied Bio-
systems), and the results were analyzed using the 7900HT Fast real-time
PCR system (Applied Biosystems).
Cell surface biotinylation and internalization assay. Cell surface
protein biotinylation and internalization assays were performed essen-
tially as described previously (34). In brief, isolated mouse ECs or
HUVECs were cultured in 6-well plates and were incubated with 0.5
mg/ml of EZ-Link NHS-SS-biotin (Pierce) in PBS for 60 min at 4°C.
Whole-cell lysates were precipitated with streptavidin-conjugated agarose
beads, and the level of VEGFR2 on the cell surface was assessed by Western
FIG 1 Specific deletion of Cdc42 in vascular ECs of CEKO embryos. Sections
from E9.5 control (A, C, and E) and CEKO (B, D, and F) embryos were stained
with antibodies against Cdc42 (A and B) and PECAM-1 (C and D). (A and B)
Cdc42 expression was detected in the ECs of control embryos (A) but not in
those of CEKO embryos (B). (C and D) PECAM-1-positive ECs were present
in both control (C) and CEKO (D) embryos. (E and F) Merged images. Cdc42
was colocalized with PECAM-1 in control (E) but not in CEKO (F) embryo
sections. Arrows indicate blood vessels. Bars, 25 m.
Jin et al.












blotting with an anti-VEGFR2 antibody. For the VEGFR2 internalization
assay, biotin-labeled cells were incubated at 37°C with 50 ng/ml VEGF in
Dulbecco’s modified Eagle’s medium (DMEM) for 5, 10, or 20 min. The
biotin tags from proteins remaining on the cell surface were removed by
washing twice with glutathione. The whole-cell lysates were precipitated
with streptavidin-agarose beads and were analyzed by Western blotting
with an anti-VEGFR2 antibody.
Boyden chamber cell migration assay. Cell migration assays were
performed in Boyden chambers (Neuro Probe), as described previously
(25). A total of 1  104 cells in 200 l serum-free DMEM were added to
each upper well, and either 1 ng/ml VEGF in DMEM or DMEM alone as
a control was added to the bottom wells. Cells were incubated for 6 h in a
37°C humidified CO2 incubator. The cells remaining in the upper wells
were removed by gently rubbing the upper membrane surface. Cells mi-
grating to the lower surface of the membrane were fixed with methanol
and were stained with modified Giemsa stain (Sigma-Aldrich).
Membrane fractionation assay. The membrane and cytosol fractions
of HUVECs were separated as described previously (35). Briefly, HUVECs
(2  105/well) were seeded in a 6-well plate and were treated with
various siRNAs for 72 h. HUVECs were permeabilized with digitonin (20
g/ml) in 200l HEPES buffer and were kept at 25°C for 5 min and on ice
for an additional 30 min (releasing cytosolic proteins without solubilizing
membrane proteins). The supernatant was collected as the cytosolic frac-
tion. Subsequently, the pellet of HUVECs was lysed using radioimmuno-
precipitation assay (RIPA) lysis buffer (Millipore) and was centrifuged at
13,000 rpm for 15 min at 4°C to remove the nuclear fraction. The super-
natant contained the membrane fraction.
Statistical analysis. Data are presented as means  standard errors
(SE). Means were compared by a 2-tailed Student t test, or by 1-way
analysis of variance (ANOVA) for the comparison of multiple groups. A P
value of0.05 was considered statistically significant.
RESULTS
Specific deletion of Cdc42 in vascular endothelial cells causes
embryonic lethality. To explore the role of Cdc42 in angiogenesis
and vasculogenesis in vivo, we generated vascular EC-specific
Cdc42 knockout mice by crossing Cdc42flox/flox mice with Tie2-
Cre mice, in which the expression of Cre recombinase was driven
by the EC-specific Tie2 promoter and enhancer (25, 26, 33). Of the
148 viable offspring, we obtained 50 Cdc42flox/flox pups (desig-
nated controls), 51 Tie2-Cre; Cdc42flox/ pups, and 47 Cdc42flox/
pups. The lack of viable Tie2-Cre; Cdc42flox/flox Cdc42 EC
knockout (CEKO) mice strongly suggests that the inactivation of
Cdc42 in ECs results in a recessive lethal phenotype. By immuno-
fluorescence staining, we verified that Cdc42 was specifically de-
leted in the ECs of E9.5 embryos (Fig. 1). Specifically, CEKO (Fig.
1B, D, and F) and control (Fig. 1A, C, and E) embryos were sec-
tioned and double-stained with antibodies against Cdc42 and
platelet endothelial cell adhesion molecule 1 (PECAM-1), a
marker for vascular ECs. PECAM-1-positive cells were detected in
FIG 2 Deletion of Cdc42 in vascular ECs caused vasculogenesis defects in
the yolk sac. (A through D) Gross examination of E8.5 control (A) and
CEKO (B) embryos showed similar morphologies. Side views of E9.5 con-
trol (C) and CEKO (D) embryos revealed that CEKO embryos had smaller
bodies. (E and F) The control E9.5 yolk sac presented highly organized
vasculature (arrows) (E), but only the blood islands were evident in the
yolk sacs of CEKO embryos (F). (G and H) Whole-mount staining with
PECAM-1 performed on the yolk sacs of control (G) and CEKO (H) em-
bryos. (I and J) Hematoxylin- and eosin-stained sections of yolk sacs from
control (I) and CEKO (J) embryos. Arrows indicate blood vessels in the
yolk sacs. Bars, 25 m.
FIG 3 Inactivation of Cdc42 impaired blood vessel formation in the trunk
region and the heart. Whole-mount staining with PECAM-1 was performed
on E9.5 control (A and C) and CEKO (B and D) embryos. Arrows indicate
blood vessels in the trunks (A) and hearts (C) of control embryos. No obvious
blood vessels were detected in the trunks (B) and hearts (D) of CEKO embryos.
Bars, 25 m.
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control (Fig. 1C and E) and CEKO (Fig. 1D and F) embryos.
However, Cdc42 was not expressed in the PECAM-1-positive cells
of CEKO embryos (Fig. 1B and F), in contrast to the controls (Fig.
1A and E).
To determine the time at which the effects of EC Cdc42 defi-
ciency occurred, we examined embryos from Cdc42flox/flox female
mice with timed pregnancies who had been mated with Tie2-
Cre; Cdc42flox/ male mice. In contrast to the Cdc42 total-
knockout embryos, which died before E6.5, no overtly abnormal
phenotype (embryo size and stage) was seen in CEKO embryos at
E8.5, compared with their littermate controls (compare Fig. 2A
and B). However, by E9.5, more than half of the CEKO embryos
showed progressively retarded growth (Fig. 2D) and had smaller
bodies than their littermate controls (Fig. 2C). In addition, heart
looping was delayed in the CEKO embryos, and the ventricular
wall was transparent (Fig. 2D). The CEKO embryos failed to sur-
vive beyond E10.5.
Vasculogenesis defects in the CEKO yolk sac and embryo.
The yolk sac is the first extraembryonic vasculogenesis site and
undergoes extensive angiogenesis during E8.5 to E10.5 (36). The
FIG 4 Blood vessel formation defects in CEKO embryos. (A through D) PECAM-1 whole-mount staining of E9.5 control (A) and CEKO (B) embryos. The head
region in the control (C) and CEKO (D) embryos was examined at a higher magnification. Red arrows indicate the organized intersomitic blood vessels (A), and
white arrows indicate the branched vessels in the brain (C). (E and F) X-Gal staining showed well-organized vessels in control embryos (arrow) (E), whereas
blood vessels were absent from CEKO embryos (F). (G through I) PECAM-1 immunofluorescence staining of cross sections of control (G) and CEKO (H and
I) embryos. A flat and elongated layer of ECs formed a patent vascular lumen in control embryos (white arrows) (G), but the ECs in CEKO embryos showed a
cuboidal epithelial morphology (yellow arrow) (H) and failed to connect to each other (white arrows) (I). Bars, 25 m.
Jin et al.












vessels of control E9.5 yolk sacs were highly organized, with
branching vitelline vessels (Fig. 2E). In CEKO yolk sacs, the vessels
were nearly completely absent; only the blood islands were evident
(Fig. 2F). To visualize the vascular ECs and confirm the vasculo-
genesis defects in CEKO yolk sacs, whole-mount PECAM-1 stain-
ing was performed. PECAM-1 staining of E9.5 control yolk sacs
showed an extensive honeycomb-like network of capillaries (Fig.
2G), while no blood vessel formation was evident in CEKO yolk
sacs (Fig. 2H). In agreement with the whole-mount staining ob-
servation, histological analysis revealed that the control E9.5 yolk
sac contained a series of blood vessels that attached to the under-
surface of the mesodermal layer of the yolk sac (Fig. 2I). In con-
trast, there was a lack of obvious blood vessels in the CEKO yolk
sac (Fig. 2J). These data suggest that Cdc42 plays an indispensable
role in vasculogenesis in the yolk sac.
To define the role of Cdc42 in embryonic blood vessel forma-
tion, we performed whole-mount PECAM-1 and LacZ staining to
visualize the morphology of the blood vessels. PECAM-1 immu-
nofluorescence staining experiments showed well-formed inter-
somitic blood vessels in control embryos (Fig. 3A) but not in
CEKO embryos (Fig. 3B). In addition, newly formed blood vessels
were detected in the hearts of control embryos (Fig. 3C) but not in
those of Tie2-Cre; Cdc42flox/ embryos (Fig. 3D). Moreover,
PECAM-1 whole-mount staining revealed normal vascular net-
works in the brains of E9.5 control embryos (Fig. 4A and C).
However, the brain vascular network was disrupted in CEKO em-
bryos (Fig. 4B and D). To exclude the possibility that the inacti-
vation of Cdc42 impairs EC differentiation and affects the expres-
sion of PECAM-1, we performed an alternative experiment using
LacZ staining to visualize blood vessels. We introduced a floxed
LacZ transgene into CEKO embryos by crossing Tie2-Cre;
Cdc42flox/ mice with Rosa26 mice. X-Gal staining showed ECs
lining the blood vessels in control embryos (Fig. 4E), while blood
vessel formation in the CEKO mutant embryos was totally dis-
rupted (Fig. 4F). Further histological analysis of controls revealed
that a flat, elongated layer of ECs formed a patent vascular lumen
(Fig. 4G). In contrast, the ECs in CEKO embryos exhibited a
cuboidal epithelial morphology and mirrored the phenotype of
integrin 1 EC knockout mice (Fig. 4H) (37). Moreover, the ECs
in CEKO embryos failed to connect to each other, indicating that
Cdc42 deletion impaired vascular integrity (Fig. 4I).
Inhibition of Cdc42 in HUVECs disrupted tube formation.
Blood flow-induced shear stress has emerged as one of the most
critical factors for vascular formation in chicken and mouse yolk
FIG 5 Interference with Cdc42 function in HUVECs disrupted tube forma-
tion. (A through D) Representative images showing tube formation in
HUVECs infected/transfected with a control green fluorescent protein (GFP)-
tagged adenovirus (A), an adenovirus expressing HA-tagged dominant nega-
tive Cdc42-T17N (B), scrambled siRNA (C), or Cdc42-specific siRNA (D). (E)
Quantitative analysis of tube length in HUVECs infected with a control GFP-
tagged adenovirus or the HA-tagged Cdc42-T17N mutant adenovirus. *, P
0.05. (F) Western blotting with anti-HA antibodies was carried out to con-
firm the overexpression of exogenous Cdc42. (G) Quantitative analysis of
tube length in HUVECs transfected with scrambled or Cdc42-specific
siRNA. (H) Western blotting showed that Cdc42 expression was lower in
cells treated with Cdc42 siRNA than in control cells. Vinculin was utilized
as a loading control.
FIG 6 Deletion of Cdc42 induced massive apoptosis during embryogene-
sis. (A and B) Hematoxylin and eosin staining analyses were performed on
E9.5 control (A) and CEKO (B) embryos. Bars, 200 m. (C and D) Higher-
magnification microphotographs of control (C) and CEKO (D) embryos.
Arrowheads (D) indicate massive pyknotic and fragmented nuclei. Bars,
25 m.
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sacs (38, 39). To exclude the influence of shear stress and deter-
mine the physiological functions of Cdc42 in capillary morpho-
genesis, we performed an assay of tube formation, a process mim-
icking sprouting during angiogenesis (30). HUVECs infected with
a control adenovirus differentiated into well-defined tube-like
structures (Fig. 5A), whereas the overexpression of a HA-tagged
Cdc42-T17N mutant (Fig. 5F), which serves as a dominant nega-
tive mutant by preventing Cdc42 from binding to GTP, disrupted
EC tube formation (Fig. 5B). To explore the endogenous physio-
logical functions of Cdc42 in tube formation, we performed an
RNAi experiment with cultured HUVECs. We have screened
three siRNA fragments targeting Cdc42 and found fragment 15 to
be an efficient inhibitor of Cdc42 expression, so this fragment was
used for the following experiments (Fig. 5H). HUVECs trans-
fected with scrambled siRNA differentiated into tube-like struc-
tures (Fig. 5C); however, tube formation was impaired when
Cdc42 expression was knocked down by siRNA treatment (Fig.
5D). Quantitative analysis confirmed that the average lengths of
the tubes in HUVECs overexpressing Cdc42-T17N were signifi-
cantly decreased from those in control cells (Fig. 5E), and in
FIG 7 Inactivation of Cdc42 caused EC apoptosis. (A through F) TUNEL assays (A and B) and PECAM-1 staining (C and D) were performed on E9.5 control
(A, C, and E) and CEKO (B, D, and F) embryos. (E and F) Merged images. Bars, 25 m. (G) Cdc42flox/flox ECs were infected by Ad-LacZ or by Ad-Cre with or
without HA-tagged wild-type Cdc42. Cell lysates were analyzed by Western blotting using various antibodies, as indicated. (H and I) The relative intensities of
cleaved caspase 3 (H) and Cdc42 (I) were analyzed quantitatively for three independent experiments. *, P 0.05.
Jin et al.












HUVECs where Cdc42 was knocked down, the tube length was
reduced by 40% from that in cells transfected with scrambled
siRNA (Fig. 5G). These data suggest that Cdc42 is necessary for
tube formation.
Cdc42 is critical for EC survival and migration. The coordi-
nated regulation of EC proliferation, migration, and apoptosis is
critical for the formation of functional blood vessels. To better
understand the underlying mechanism by which Cdc42 regulates
new blood vessel formation, we performed histological analysis of
E9.5 CEKO and control embryos. Hematoxylin and eosin staining
revealed dramatic increases in the numbers of pyknotic and frag-
mented nuclei, both of which are signs of apoptosis, as an outcome
of Cdc42 deletion (Fig. 6B and D). No apoptotic cells were evident
in control embryos (Fig. 6A and C). It is not clear whether the
apoptotic cells were ECs (due to the inactivation of Cdc42) or
non-ECs. To examine the role of Cdc42 in controlling EC survival,
we performed TUNEL assays and PECAM-1 double staining on
CEKO (Fig. 7B, D, and F) and control (Fig. 7A, C, and E) embryos.
In agreement with the histology results, Cdc42 inactivation in-
duced massive apoptosis, with increased numbers of apoptotic
ECs in CEKO embryos (Fig. 7B). Interestingly, many of the apop-
totic cells were negative for PECAM-1 staining (Fig. 7F). It has
been reported that Cre recombinase, the expression of which was
driven by the Tie2 promoter and enhancer, was expressed not only
in vascular ECs but also in non-ECs, such as hematopoietic cells
(26). It is possible that the PECAM-1-negative apoptotic cells re-
sulted from the deletion of Cdc42 in hematopoietic cells. Another
possibility is that the apoptotic ECs and non-ECs we detected in
CEKO embryos were caused by a secondary effect due to dysfunc-
tional blood vessels. To address this question, we isolated ECs
from the hearts of neonatal Cdc42flox/flox mice. Flow cytometric
analysis showed that the percentage of cells positive for VE-cad-
herin (a marker of EC) was more than 80% (data not shown). The
cultured Cdc42flox/flox ECs were infected with recombinant ad-
enoviruses encoding Cre recombinase or LacZ as a control. The
Cdc42 expression level was significantly decreased after 48 h in
ECs infected with Ad-Cre, and this effect was maintained as long
as 96 h after virus inoculation (data not shown). In agreement
with the in vivo results, levels of cleaved caspase 3, a marker for
apoptosis, were increased in Cdc42-null ECs, and this effect was
reversed by the reexpression of wild-type Cdc42 (Fig. 7G, H, and
I). These results suggest that Cdc42 is critical for EC survival dur-
ing blood vessel formation.
EC proliferation and migration are essential steps for vasculo-
genesis and angiogenesis. To determine the role of Cdc42 in EC
proliferation, we stained embryos with phosphorylated histone
H3 (pH3), a marker for proliferation. We did not detect any sig-
nificant differences between the levels of pH3-positive cells in
CEKO and control embryos (Fig. 8). In addition, we also per-
formed BrdU incorporation experiments on cultured Cdc42
knockdown (Fig. 9D, E, and F) and control (Fig. 9A, B, and C)
HUVECs. Consistently, we observed that the inactivation of
Cdc42 had no significant effect on cell cycle progression in-
duced by fetal bovine serum (Fig. 9G), suggesting that Cdc42
does not play a role in EC proliferation in angiogenesis during
embryo development.
To determine the function of Cdc42 in EC migration, we
performed Boyden chamber analysis. Figure 9H shows that
Cdc42 deletion significantly decreased the level of EC migra-
tion from that for the control. To further confirm the impor-
tance of Cdc42 in EC migration, we performed a rescue exper-
iment by overexpressing wild-type Cdc42. As expected,
overexpression of the wild-type Cdc42 rescued EC migration
defects.
Deletion ofCdc42 in ECs decreased the level ofVEGFR2pro-
tein on the plasmamembrane. Cdc42 plays critical roles in regu-
lating protein hemostasis, including gene transcription, protein
trafficking, endocytosis, and degradation (10, 40, 41). To deter-
mine the molecular mechanisms of Cdc42 in regulating blood
vessel formation, we first isolated ECs from Cdc42flox/flox mouse
hearts and then infected them with Ad-Cre or Ad-LacZ. We per-
formed Western blotting to examine the effect of deletion of
Cdc42 on plasma membrane receptors that are important for new
blood vessel formation. We observed that the deletion of Cdc42
had no significant influence on PECAM-1, VE-cadherin, and
VEGFR1 protein levels but significantly decreased the VEGFR2
level (Fig. 10A and B). To confirm the Western blotting result, we
performed VEGFR2 and PECAM-1 double staining in CEKO
(Fig. 10E and F) and control (Fig. 10C and D) E9.5 embryos. In
agreement with data presented above (Fig. 4H and I), Cdc42 in-
activation had no effect on EC PECAM-1 staining in CEKO em-
bryos (Fig. 10F) compared to the results from the controls (Fig.
10D). However, we found that the level of VEGFR2 staining in the
CEKO embryos was significantly decreased (Fig. 10E) from that in
control embryos (Fig. 10C). Due to the importance of VEGFR2 in
blood vessel formation, these data strongly suggest that impaired
VEGFR2-mediated signal transduction is likely one of the under-
lying reasons for EC apoptosis and vasculogenesis defects in
CEKO embryos.
FIG 8 Deletion of Cdc42 has no effect on EC proliferation in vivo. (A through
F) Sections from E9.5 control (A, C, and E) and CEKO (B, D, and F) embryos
were stained with antibodies against pH3 (A and B) and PECAM-1 (C and D).
The numbers of pH3 and PECAM-1 double-positive cells in control (E) and
CEKO (F) embryos are comparable. Bars, 25 m.
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In order to determine how Cdc42 influences VEGFR2 levels,
we performed real-time PCR experiments to assess the effect of
Cdc42 on VEGFR2 transcription. Our results showed that the
mRNA levels of VEGFR2 in Cdc42-null ECs were comparable to
those for the control (data not shown), suggesting that the regu-
lation of VEGFR2 protein levels by Cdc42 is mediated through
posttranscriptional mechanisms. Using a plasma membrane-im-
permeant biotin (EZ-Link NHS-SS-biotin; Pierce) probe, which
can bind to lysine residues on cell surface proteins, we found that
VEGFR2 levels on the plasma membrane surface were signifi-
cantly lower in Cdc42-null mouse ECs (Ad-Cre) than in control
cells (Ad-LacZ) (Fig. 10G and H).
To further determine how Cdc42 influences VEGFR2 levels,
we knocked down Cdc42 in cultured HUVECs using siRNA
against Cdc42 and performed a VEGFR2 internalization analysis.
For this experiment, we first labeled cell surface proteins with
biotin and then stimulated HUVECs with VEGF for the times
indicated in Fig. 11A. Subsequently, the biotin tags from proteins
remaining on the cell surface were removed by washing twice with
glutathione. The internalized VEGFR2 fragments were precipi-
tated by streptavidin-agarose beads and were detected by Western
blotting with an anti-VEGFR2 antibody. We detected a significant
increase in the amount of a 75-kDa fragment in Cdc42-knock-
down HUVECs (Fig. 11A, right) over that in the controls (Fig.
11A, left). Because this 75-kDa fragment could be precipitated by
streptavidin and recognized by an antibody against the C-ter-
minal domain of VEGFR2, it likely contains the full transmem-
brane domain, the cytosolic domain, and a portion of the ex-
tracellular domain of VEGFR2. We also detected a 130-kDa
band in HUVECs, recognized by the anti-VEGFR2 antibody; its
expression was independent of the presence of Cdc42. How-
ever, this band was not present in mouse ECs (Fig. 10G). The
inactivation of Cdc42 resulted in decreased expression of
VEGFR2 on the cell surface and increased expression of a 75-
FIG 9 Inactivation of Cdc42 did not influence the cell cycle progression of HUVECs but impaired EC migration. (A through F) Cultured HUVECs were
transfected with scrambled siRNA (A, B, and C) or Cdc42 siRNA (D, E, and F). Three days later, BrdU was added and was incubated for 18 h. BrdU (A and D)
and VE-cadherin (B and E) staining was then performed. (C and F) Merged images. Bars, 50 m. (G) Quantitative analysis of BrdU incorporation shows no
significant difference between control and Cdc42 knockdown cells with or without fetal bovine serum (FBS) stimulation. (H) Cultured Cdc42flox/flox ECs were
infected with Ad-LacZ, Ad-Cre, or Ad-Cre plus Ad-Cdc42 (wild type). The infected ECs were subjected to Boyden chamber analysis in response to VEGF (1
ng/ml). *, P 0.05.
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kDa VEGFR2 fragment in the cytosol (Fig. 10G and 11A and B),
suggesting that Cdc42 deletion might increase VEGFR2 shed-
ding. To confirm that the 75-kDa fragment came from
VEGFR2 shedding, we infected cultured HUVECs with an ad-
enovirus that encodes C-terminally HA-tagged wild-type
VEGFR2. Western blotting showed that the 75-kDa VEGFR2
fragment can be recognized by both anti-HA and anti-VEGFR2
antibodies (data not shown), suggesting that the 75-kDa frag-
ment is a part of VEGFR2. Moreover, we overexpressed C-ter-
minally HA- and His-tagged wild-type VEGFR2 in HEK 293
cells. We found that nickel beads or anti-HA antibody-conju-
gated agarose beads pulled down the 75-kDa VEGFR2 frag-
ment (data not shown). These results further confirmed that
the 75-kDa fragment is a part of VEGFR2. The level of cytosolic
biotinylated full-length VEGFR2 in unstimulated Cdc42
knockdown HUVECs (incubated at 37°C for 20 min without
VEGF stimulation) was higher than that in the controls (Fig.
11A), suggesting that the deletion of Cdc42 might enhance
VEGFR2 autointernalization. Furthermore, we examined the
effect of knocking down Cdc42 on VEGF-stimulated signal
transduction. We found that Cdc42 inactivation can inhibit
VEGF-induced Erk phosphorylation (Fig. 11C and D), sup-
porting our hypothesis that the inactivation of Cdc42 interferes
with VEGF signal transduction.
FIG 10 Deletion of Cdc42 in ECs decreased the VEGFR2 protein level. (A) Primary ECs isolated from Cdc42flox/flox mouse hearts were infected by Ad-Cre or by
Ad-LacZ as a control. Whole-cell lysates were prepared and were blotted with antibodies against VEGFR1, VEGFR2, VE-cadherin, PECAM-1, Cdc42, and
vinculin, as indicated. (B) Quantitative analysis shows that the VEGFR2 level was significantly decreased in Cdc42-null ECs. (C through F) Sections of E9.5
control (C and D) and CEKO (E and F) embryos were stained by antibodies against VEGFR2 (green) and PECAM-1 (red). Blood vessels are indicated by arrows,
and dashed lines indicate the boundary of the neural tube (NT). Bars, 25m. (G) The membrane surface proteins of primary mouse ECs were labeled with biotin
and were pulled down using streptavidin-conjugated beads. The precipitated complex was then analyzed by Western blotting using anti-VEGFR2 antibodies. (H)
The intensities of VEGFR2 75-kDa fragment bands from three independent experiments were quantitatively analyzed. *, P 0.05.
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ding. The ADAM family of proteases cleaves the ectodomains of
growth factors and their receptors (42, 43). To determine whether
ADAMs are involved in VEGFR2 shedding in Cdc42-depleted
ECs, we added TAPI-1, an inhibitor of ADAMs (44), to HUVECs
in which Cdc42 had been knocked down. We found that TAPI-1
decreased the level of production of the 75-kDa fragment with or
without VEGF stimulation (Fig. 12A and B), suggesting that one
or several ADAM family members are responsible for the produc-
tion of this fragment. Consistently, we observed that TAPI-1 can
reverse cell apoptosis induced by the deletion of Cdc42 in cultured
primary mouse ECs (Fig. 12C to N). Among 27 ADAM family
members, ADAM17 and ADAM10 have been reported to func-
tion as “sheddases” for VEGFR2 (45, 46). Using a more specific
ADAM inhibitor (INCB3619) that attenuates the activity of
ADAM10, ADAM17, and metalloproteases (MMPs) (47), we
observed results similar to those obtained with TAPI-1 (data
not shown). Furthermore, we examined the effects of TAPI-1
and INCB3619 on the production of cleaved caspase 3. We
discovered that deletion of Cdc42 increased the production of
cleaved caspase 3, suggesting that the level of EC apoptosis was
increased. Notably, we found that both TAPI-1 and INCB3619
can inhibit the production of cleaved caspase 3 induced by the
deletion of Cdc42 in ECs (Fig. 13A and B), indicating that
ADAM10, ADAM17, and/or MMPs are very likely the candi-
date enzymes for VEGFR2 shedding.
To identify which ADAM family member(s) is involved in the
production of the 75-kDa VEGFR2 fragment, we stimulated
HUVECs with phorbol-12-myristate-13-acetate (PMA) or iono-
mycin (IM), which have been reported to activate ADAM17 or
ADAM10, respectively (45, 46, 48). We found that treatment with
PMA, but not IM (data not shown), increased the production of
the 75-kDa VEGFR2 fragment, indicating that ADAM17 triggers
VEGFR2 shedding in HUVECs (Fig. 13C and D). To further test
this hypothesis, we knocked down ADAM17 from Cdc42-de-
pleted HUVECs and assessed the level of the 75-kDa VEGFR2
fragment in these cells. Consistent with the TAPI-1 result, knock-
ing down ADAM17 significantly inhibited the production of the
75-kDa VEGFR2 fragment (Fig. 13E and F). These data strongly
indicate that ADAM17 is the sheddase that mediates VEGFR2
cleavage in Cdc42-depleted HUVECs. Moreover, we performed
membrane fractionation assays and examined the role of
ADAM17 in VEGFR2 shedding. Our data showed that inactiva-
tion of Cdc42 decreased the amount of full-length VEGFR2, and
FIG 11 Inactivation of Cdc42 promoted VEGFR2 shedding and impaired VEGF-induced Erk phosphorylation. (A) HUVECs were transfected with either
scrambled siRNA (left) or Cdc42-targeted siRNA (right) and were then labeled with biotin. After treatment with 50 ng/ml VEGF from 0 to 20 min, the biotin tags
on the cell surface were removed by L-glutathione (reduced), and the internalized biotin-labeled proteins were analyzed by Western blotting with anti-VEGFR2
antibodies. Full-length VEGFR2 (230 kDa) and the smaller VEGFR2 fragments detected (130 kDa and 75 kDa) are indicated by arrows. Cdc42 expression was
assessed to confirm the efficiency of siRNA treatment against Cdc42, and vinculin was utilized as a loading control. (B) Quantitative analysis shows that Cdc42
knockdown significantly increased the production of the 75-kDa VEGFR2 fragment. *, P 0.05. (C) HUVECs were transfected with scrambled siRNA or Cdc42
siRNA and were challenged with VEGF at the indicated time points. Whole-cell lysates were analyzed by Western blotting with specific antibodies against
phosphorylated Erk (P-Erk) and total Erk (T-Erk). (D) Quantitative data show that Cdc42 knockdown significantly decreased the P-Erk level in response to
VEGF stimulation at 15 min.
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that deletion of ADAM17 prevented this decrease, on the mem-
brane (Fig. 13G). At the same time, inactivation of Cdc42 en-
hanced the production of the 75-kDa VEGFR2 fragment, and in-
hibition of ADAM17 attenuated the amount of 75-kDa VEGFR2,
on the membrane (Fig. 13G). PECAM-1 and 	-tubulin were blot-
ted as the markers for the membrane and cytosol fractions, respec-
tively. Cdc42 cycles between the plasma membrane and the
cytosol, so we detected Cdc42 expression in both the mem-
brane and cytosol fractions. VEGFR2 and ADAM17 contain
transmembrane domains, and we detected the signals of
VEGFR2 and ADAM17 only in the membrane fraction, because
the method we utilized for fractionation cannot separate the
plasma membrane from the cytosolic vesicles.
Next, we examined the effect of ADAM17 on Cdc42 deletion-
induced EC apoptosis by determining the levels of the proapop-
totic protein Bax and the antiapoptotic protein Bcl-2. In line with
our previous results, we found that inhibition of Cdc42 increased
Bax and decreased Bcl-2 protein levels (Fig. 14A and B), results
consistent with our finding that Cdc42 plays an indispensable role
in EC survival. Importantly, the inactivation of ADAM17 can re-
verse the Cdc42 deletion-induced Bax increase and Bcl-2 decrease,
suggesting that ADAM17 is an important effector of Cdc42 in
maintaining EC survival. Consistently, the results of flow cyto-
metric analysis experiments showed that the inactivation of Cdc42
increased HUVEC apoptosis, by comparison of Cdc42 knock-
down cells (Fig. 14D) to control cells (Fig. 14C). Cdc42 deletion-
induced apoptosis could be reversed by knocking down ADAM17
(Fig. 14E and F). To further confirm the importance of ADAM17
in Cdc42 deletion-induced HUVEC apoptosis, we performed
TUNEL analysis. Our data showed that knocking down Cdc42
increased HUVEC apoptosis (Fig. 14I and J) over that for the
control (Fig. 14G and H) and that inactivation of ADAM17 sig-
nificantly decreased Cdc42 deletion-induced HUVEC apoptosis
(Fig. 14K, L, and M).
To determine whether ADAM17-mediated VEGFR2 shedding
is the cause of EC survival and migration defects induced by Cdc42
deletion, we isolated primary ECs from homozygous Cdc42flox/flox
mice. The cultured Cdc42flox/flox ECs were infected with Ad-LacZ,
Ad-Cre, or Ad-Cre plus Ad-HA-VEGFR2. Cell lysates were then
analyzed by a Western blotting assay using cleaved caspase 3
FIG 12 TAPI inhibited ADAM17-mediated VEGFR2 shedding and EC apoptosis induced by the inactivation of Cdc42. (A) HUVECs transfected with Cdc42
siRNA were either left untreated or treated with TAPI-1 (50 M) for 4 h, and internalized VEGFR2 was then analyzed by Western blotting. Samples were also
blotted with antibodies against Cdc42 and vinculin. (B) Quantitative analysis results show that TAPI treatment significantly decreased the level of production of
75-kDa VEGFR2 fragments. (C through N) Cultured Cdc42flox/flox ECs were infected either with Ad-LacZ (C through F), with Ad-Cre without further treatment
(G through J), or with Ad-Cre plus TAPI-1 (50 M) (K through N). TUNEL assays, PECAM-1 staining, and Hoechst staining for nuclei were then performed.
Bars, 25 m.
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antibodies. We discovered that deletion of Cdc42 increased the
production of cleaved caspase 3 and that overexpression of
VEGFR2 hampered the production of cleaved caspase 3, indicat-
ing that VEGFR2 can reverse Cdc42 deletion-induced EC apopto-
sis (Fig. 15A and B). However, we noted that overexpression of
VEGFR2 cannot reverse Cdc42 deletion-induced EC migration
defects, indicating that VEGFR2 shedding is not responsible for
the migration defects in Cdc42-null ECs (Fig. 15C). All these data
FIG 13 Inhibition of ADAM17 decreased the production of the 75-kDa VEGFR2 fragment. (A) Cultured mouse Cdc42flox/flox ECs were infected with
Ad-Cre or Ad-LacZ and were then incubated with or without TAPI-1 (50 M) or INCB3619 (2 M) for 4 h. Cell lysates were reacted with antibodies for
cleaved caspase 3 (top), Cdc42 (center), or vinculin (bottom). (B) The intensities of bands from three independent experiments were quantitatively
analyzed. *, P  0.05. (C) HUVECs were either left untreated or treated with PMA (25 ng/ml) for 1 h and were then analyzed by Western blotting using
antibodies against VEGFR2 and vinculin. (D) The intensities of bands from three independent experiments were quantitatively analyzed. (E) HUVECs
transfected with Cdc42 siRNA, alone or together with ADAM17 siRNA, were incubated with or without VEGF (50 ng/ml) for 30 min and were then
subjected to an internalization assay (top). The cell lysates from each sample were analyzed by Western blotting with antibodies against Cdc42, ADAM17,
and vinculin, as indicated. (F) The relative intensities of 75-kDa VEGFR2 fragments were quantitatively analyzed. (G) HUVECs transfected with
scrambled siRNA, Cdc42 siRNA alone, or Cdc42 siRNA together with ADAM17 siRNA. Cellular membrane and cytosol fractions were separated and were
then blotted with various antibodies as indicated.
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strongly suggest that ADAM17-mediated VEGFR2 shedding is a
major cause of induction of EC apoptosis in blood vessel forma-
tion defects in CEKO embryos.
DISCUSSION
As an essential molecular switch in signal transduction, Cdc42 has
been shown to play a critical role in regulating cell proliferation,
migration, differentiation, and apoptosis (10). However, the pu-
tative function and molecular mechanisms of Cdc42 in new blood
vessel formation in vivo remain unclear due to the early embryonic
lethality (E6.5) exhibited by Cdc42 total-knockout embryos. Us-
ing the Cre/LoxP system, we found that the inactivation of Cdc42
in ECs induced embryonic lethality (E10.5) and blood vessel for-
mation defects. Moreover, we demonstrated that Cdc42 is a piv-
otal regulator of EC migration and survival but does not play a role
in regulating EC proliferation. Furthermore, we observed that
Cdc42 deletion decreased the levels of VEGFR2 in ECs through
ADAM17-mediated VEGFR2 shedding. Inhibition of ADAM17
activity or overexpression of VEGFR2 can partially reverse EC
apoptosis induced by Cdc42 deletion. Taking our findings to-
FIG 14 Inactivation of ADAM17 reversed Cdc42 deletion-induced EC apoptosis. (A) Cell lysates of HUVECs transfected with scrambled siRNA, Cdc42
siRNA, or Cdc42 siRNA plus ADAM17 siRNA were analyzed by Western blotting using specific antibodies against Bax or Bcl-2. (B) The intensities of
bands from three different experiments were quantitatively analyzed. (C through F) HUVECs were transfected with scrambled siRNA (C), Cdc42 siRNA
(D), or Cdc42 siRNA plus Adam17 siRNA (E) and were cultured for 72 h. HUVEC nuclei were then labeled by propidium iodide (PI), and apoptotic cells
were labeled by annexin V. (F) Quantitative analysis data show that ADAM17 knockdown significantly decreased Cdc42 deletion-induced apoptosis. (G
through M) TUNEL staining revealed increased HUVEC apoptosis in Cdc42 knockdown cells (I and J) relative to that in control cells (G and H). The
silencing of ADAM17 significantly reduced HUVEC apoptosis induced by the deletion of Cdc42 (K and L). The percentage of apoptotic HUVECs was
quantitatively analyzed (M).
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gether, we conclude that Cdc42 plays a crucial role in EC survival
and migration and that deletion of Cdc42 impairs blood vessel
formation during embryogenesis (Fig. 16).
Vascular endothelial cells line the entire circulatory system and
are the sensors and responders for blood vessel formation (3, 49).
Previous studies have shown the importance of Cdc42 in regulat-
ing EC cytoskeleton organization and adherens junction assembly
(50, 51). Here, we showed that Cdc42 deletion in ECs reduced the
levels of VEGFR2 on the cell surface and increased the production
of a 75-kDa membrane-associated C-terminal VEGFR2 fragment
through ADAM17. Combining these findings with previous stud-
ies, we would propose that Cdc42 functions, at least in two ways,
to control proangiogenic signals. First, Cdc42 could mediate im-
portant signal transduction in ECs during vascular development.
Following the stimulation of ECs by growth factors or the extra-
cellular matrix (e.g., fibronectin), activated Cdc42 can bind to its
downstream effectors, stimulate EC migration, and maintain the
viability of ECs, which are critical events for angiogenesis and
vasculogenesis. Inactivation of Cdc42 may interfere with the abil-
ity of growth factors and/or integrins to trigger signaling events,
thus leading to the disruption of blood vessel formation. Second,
Cdc42 is also actively involved in regulating the levels of VEGFR2
FIG 15 Overexpression of VEGFR2 reversed Cdc42 deletion-induced EC apoptosis but not migration defects. (A) Lysates from primary cultured mouse ECs
infected with Ad-LacZ, Ad-Cre, or Ad-Cre plus Ad-VEGFR2 were analyzed by Western blotting using different antibodies as indicated. (B) The intensities of
bands for cleaved caspase 3 and VEGFR2 were quantitatively analyzed. *, P 0.05. (C) Cultured primary mouse ECs were infected with Ad-LacZ, Ad-Cre, or
Ad-Cre plus Ad-VEGFR2 and were subjected to Boyden chamber analysis following the response to VEGF (1 ng/ml). *, P 0.05.
FIG 16 Working model of Cdc42 in tube formation and vasculogenesis. Inactivation of Cdc42 induced EC survival and migration defects. The increased
ADAM17-mediated VEGFR2 shedding contributed to the enhancement of EC apoptosis.
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on the cell surface. Cdc42 deletion in ECs increased the produc-
tion of a 75-kDa VEGFR2 fragment and caused a reduction in the
level of full-length VEGFR2 on the membrane. This function is
important for controlling the magnitude and duration of VEGF-
initiated proangiogenic signals and for preventing the premature
termination of VEGF signals. Interestingly, previous studies have
shown that the secreted VEGFR2 (sVEGFR2) extracellular do-
main competes with VEGFR2 by binding to VEGF (52). The ap-
parent size of the VEGFR2 extracellular domain (around 150 kDa)
generated by ADAM17-mediated VEGFR2 shedding is very close
to the size of sVEGFR2. It is possible that this putative VEGFR2
extracellular domain competes for VEGF and inhibits VEGF-
stimulated signaling.
ECs need to coordinate and properly respond to multiple ex-
tracellular stimuli, including growth factors, the extracellular ma-
trix, and cell-cell adhesion, to maintain cell survival (1, 53, 54). We
show that Cdc42 deletion in ECs dramatically increased EC apop-
tosis both in vivo and in vitro and that inactivation of ADAM17 or
overexpression of VEGFR2 reversed Cdc42 deletion-induced EC
apoptosis. VEGF plays an essential role in regulating EC survival,
and Cdc42 deletion compromised VEGFR2 homeostasis; thus,
aberrant VEGFR2-mediated signal transduction is likely one of
the causes of EC apoptosis. Cdc42 is located at the convergence of
many signal transduction pathways, including integrins and re-
ceptor tyrosine kinases (11). Because overexpression of VEGFR2
or knockdown of ADAM17 cannot fully reverse EC apoptosis, it is
possible that other Cdc42-regulated signal transduction pathways
are also involved in controlling EC survival. In addition, we
showed that the decrease in VEGFR2 had no influence on EC
proliferation. It is possible that when VEGFR2 expression is de-
creased, ECs rely on other growth factors to stimulate prolifera-
tion. We noticed significant increases in the levels of the 75-kDa
VEGFR2 fragment in Cdc42-depleted HUVECs. The function of
this 75-kDa VEGFR2 fragment remains unclear. The 75-kDa
fragment may bind to its downstream effectors to elicit specific
physiological functions. It would be interesting to determine
the relationship between the 75-kDa fragment and EC migra-
tion defects.
In our studies we found that three fragments of VEGFR2 (230
kDa, 130 kDa, and 75 kDa) were pulled down by streptavidin
beads. Previous studies have shown that PMA stimulation can
increase ADAM17-mediated VEGFR2 shedding and generate a
150-kDa N-terminal VEGFR2 fragment (48). We found that the
deletion of Cdc42 enhanced ADAM17-mediated VEGFR2 shed-
ding and increased the production of a C-terminal 75-kDa frag-
ment. However, the production of the 130-kDa VEGFR2 frag-
ment is not affected by Cdc42 deletion and is inhibited by TAPI-1.
Interestingly, knocking down ADAM17 does not influence the
production of the 130-kDa fragment. All of these data strongly
suggest that the 130-kDa VEGFR2 fragment is generated through
another ADAM family enzyme and that Cdc42 does not play a
direct role in its regulation.
The underlying molecular mechanisms by which Cdc42 regu-
lates ADAM17-mediated VEGFR2 shedding remain to be deter-
mined. Previous studies have reported that the mature form of
ADAM17 is enriched in lipid (membrane) rafts and that depletion
of cholesterol, which disrupts the structure of lipid rafts, increases
ADAM-17-mediated substrate shedding (55). Interestingly, the
maintenance of lipid rafts relies on polarized actin, which is di-
rected by Cdc42 (10, 56). Therefore, Cdc42 may play a positive
role in limiting the amount of ADAM17 in lipid rafts and prevent-
ing its interaction with VEGFR2. Deletion of Cdc42 may disrupt
the lipid raft structure, due to the loss of support from actin, and
release the mature ADAM17 to induce abnormal VEGFR2 shed-
ding. It is well documented that Cdc42 plays an essential role in
regulating receptor endocytosis, recycling, and trafficking (40,
57). Thus, it is also possible that Cdc42 deletion interferes with
VEGFR2 internalization and trafficking. Consequently, VEGFR2
may be sorted to the proteasome for degradation, reducing
VEGFR2 levels in Cdc42-deficient ECs.
In addition to VEGF signaling stimulation, extracellular ma-
trix and integrin receptors are also important for blood vessel
formation (53, 54). Deletion of fibronectin or integrins in ECs
induces angiogenesis and vasculogenesis defects (53, 54). Since
Cdc42 is an important signaling mediator of integrins, its inacti-
vation may also disrupt integrin-mediated signal transduction. A
recent report showed that the deletion of 1 integrin in ECs inter-
fered with EC polarity via a Par3-dependent mechanism (37). Our
data show that Cdc42 deletion caused EC remodeling defects, and
Cdc42-null ECs showed a cuboidal epithelial morphology instead
of the long, thin morphology characteristic of ECs. Cdc42 can
form a complex with Par6, Par3, and atypical protein kinase C
(aPKC), and this complex is critical for cell polarity (10, 58). The
loss of Cdc42 in ECs disrupts complex formation between these
proteins and interferes with cell polarity. N-WASP and Arp2/3 are
other important effectors of Cdc42 that are involved in cell polar-
ity. Cdc42-null ECs may not properly regulate actin polarization,
and this is another possible mechanism for the observed defects in
EC remodeling.
In conclusion, we have demonstrated that Cdc42 plays a
pivotal role in ECs during blood vessel formation. The results
generated from the in vitro and in vivo studies suggest that
Cdc42 functions as a signal transducer and an active regulator
of VEGFR2 to properly guide the EC response to VEGF stimu-
lation.
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